Comparison
Bremelanotide vs. Sermorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Growth
CAS no.
189691-06-3
86168-78-7
Molecular weight
1025.18 g/mol
3358 g/mol
Half-life
2.7 h
0.2 h
Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHYADAIFTNSYRKVLGQLSARKLLQDIMSRMechanism of action
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
5
of which in humans
5
3
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
2
3